selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease
selectION Demonstrates Safety and Disease-Modifying Mechanism of Action of its Investigational Drug, si-544, in Phase 1b Proof-of-Concept Trial in Psoriasis, a T Cell-Mediated Autoimmune Disease GlobeNewswire October 21, 2025 Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients si-544 is the first highly potent and selective […]